临床研究中的过程评价(Process evaluation)是什么意思?

2018-11-29 褚红玲 赵一鸣 临床流行病学和循证医学

这样一个研究:主研究是一项正在中国农村开展的大型整群随机对照试验,评估减少钠摄入量对降低脑卒中发病和死亡的效果。该研究自2014年启动以来,在河北、辽宁、宁夏、山西和陕西五省纳入10个县,共600个村,每村35人,合计21000名受试者参加。所有被纳入的村被按照1:1的比例随机分成干预组和对照组。干预组会接受免费提供的低钠盐以取代普通食用盐。对照组照常自行购买和食用普通盐。具体的研究方案已经在

这样一个研究:主研究是一项正在中国农村开展的大型整群随机对照试验,评估减少钠摄入量对降低脑卒中发病和死亡的效果。该研究自2014年启动以来,在河北、辽宁、宁夏、山西和陕西五省纳入10个县,共600个村,每村35人,合计21000名受试者参加。所有被纳入的村被按照1:1的比例随机分成干预组和对照组。干预组会接受免费提供的低钠盐以取代普通食用盐。对照组照常自行购买和食用普通盐。具体的研究方案已经在Am Heart J发表,详见参考文献。 我们为什么要做过程评价呢?我们希望通过过程评价,了解在SSaSS项目的干预过程中,干预的实施情况、受试者对干预的依从程度,以及受试者在试验过程中对干预的认知等。过程评价的结果既能帮助我们深度了解该研究的实施情况,并辅助解释研究结果,还可以为后续干预措施的推广提供改进建议和依据。 在我们长期进行临床研究的过程中,可能会发现,有的干预措施从理论上讲应该会有较好的研究效果,但是研究结果却与我们的设想大相径庭。尤其是一些复杂的干预措施,或者是多中心的临床研究等。这时候,我们很可能就会坐在电脑前,看着一堆冷冰冰的数据冥思苦想,究竟是为什么会这样,然后把数据翻来覆去做

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2187293, encodeId=2740218e29393, content=PRO, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/oJC24d8duxNCJgJwTp2WZDNxZJxq44qLZNwsVFg9o07ia5R0QAlPaAmgJffaJumYia9JpKQ0aFZNrib7ibsW4rib5Zw/132, createdBy=344a2446383, createdName=廖医生, createdTime=Wed Feb 14 16:38:50 CST 2024, time=2024-02-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1976981, encodeId=fe0419e6981e4, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Sep 26 20:28:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444464, encodeId=c1ce1444464c7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Dec 01 14:28:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602091, encodeId=eb9e16020911d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Dec 01 14:28:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354019, encodeId=e0023540198f, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Nov 29 23:59:36 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2024-02-14 廖医生 来自广东省

    PRO

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2187293, encodeId=2740218e29393, content=PRO, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/oJC24d8duxNCJgJwTp2WZDNxZJxq44qLZNwsVFg9o07ia5R0QAlPaAmgJffaJumYia9JpKQ0aFZNrib7ibsW4rib5Zw/132, createdBy=344a2446383, createdName=廖医生, createdTime=Wed Feb 14 16:38:50 CST 2024, time=2024-02-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1976981, encodeId=fe0419e6981e4, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Sep 26 20:28:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444464, encodeId=c1ce1444464c7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Dec 01 14:28:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602091, encodeId=eb9e16020911d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Dec 01 14:28:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354019, encodeId=e0023540198f, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Nov 29 23:59:36 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2019-09-26 linlin2312
  3. [GetPortalCommentsPageByObjectIdResponse(id=2187293, encodeId=2740218e29393, content=PRO, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/oJC24d8duxNCJgJwTp2WZDNxZJxq44qLZNwsVFg9o07ia5R0QAlPaAmgJffaJumYia9JpKQ0aFZNrib7ibsW4rib5Zw/132, createdBy=344a2446383, createdName=廖医生, createdTime=Wed Feb 14 16:38:50 CST 2024, time=2024-02-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1976981, encodeId=fe0419e6981e4, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Sep 26 20:28:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444464, encodeId=c1ce1444464c7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Dec 01 14:28:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602091, encodeId=eb9e16020911d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Dec 01 14:28:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354019, encodeId=e0023540198f, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Nov 29 23:59:36 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2018-12-01 huagfeg
  4. [GetPortalCommentsPageByObjectIdResponse(id=2187293, encodeId=2740218e29393, content=PRO, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/oJC24d8duxNCJgJwTp2WZDNxZJxq44qLZNwsVFg9o07ia5R0QAlPaAmgJffaJumYia9JpKQ0aFZNrib7ibsW4rib5Zw/132, createdBy=344a2446383, createdName=廖医生, createdTime=Wed Feb 14 16:38:50 CST 2024, time=2024-02-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1976981, encodeId=fe0419e6981e4, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Sep 26 20:28:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444464, encodeId=c1ce1444464c7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Dec 01 14:28:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602091, encodeId=eb9e16020911d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Dec 01 14:28:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354019, encodeId=e0023540198f, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Nov 29 23:59:36 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2018-12-01 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=2187293, encodeId=2740218e29393, content=PRO, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/oJC24d8duxNCJgJwTp2WZDNxZJxq44qLZNwsVFg9o07ia5R0QAlPaAmgJffaJumYia9JpKQ0aFZNrib7ibsW4rib5Zw/132, createdBy=344a2446383, createdName=廖医生, createdTime=Wed Feb 14 16:38:50 CST 2024, time=2024-02-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1976981, encodeId=fe0419e6981e4, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Sep 26 20:28:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444464, encodeId=c1ce1444464c7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Dec 01 14:28:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602091, encodeId=eb9e16020911d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Dec 01 14:28:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354019, encodeId=e0023540198f, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Nov 29 23:59:36 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2018-11-29 惠映实验室

    学习了,谢谢分享。

    0

相关资讯

人工智能改变中西医临床研究与实践

中国中医药信息研究会临床研究分会在北京召开了第三届学术年会,主题为“智能信息两化融合,改变中西医临床研究与实践”,会议盛况引人关注。会后至今已半月有余,我没有停止思考,从最初的会议忙碌到现在思想沉淀下来,结合自己从事的中医临床研究领域,联想到相关领域将要开展的合作,把一连串的联想和感想写下来,尽力把一些问题梳理清楚,分享给不同学科、不同行业的同道中人,也诚恳期待回音、争鸣,期盼更实质的合作机遇。

异种移植临床研究指导意见(2018建议版)

简要介绍: 为推进异种移植临床研究的安全、顺利开展,规范异种移植临床研究行为,根据相关法律和规范,中华医学会器官移植学分会异种移植学组从总则、项目申请与审查、技术标准、伦理要求、生物安全、项目管理、供体要求、受者选择、项目实施、追踪随访等方面,制定了异种移植临床研究指导意见(2018 建议版)。

抗癫痫Ⅰ类新药派恩加滨获准临床研究

记者从中国科学院上海药物研究所获悉,该所南发俊课题组和高召兵课题组自主研发的抗癫痫Ⅰ类新药派恩加滨片已获得国家市场监督管理总局核准签发的药物临床试验批件,获准开展临床研究。

中国1类新药分布及临床试验概况分析

我国有近6700余个药物品种处于临床研究阶段,临床研究数目多、临床研究药物品种多。临床数目多,则是临床研究情况的表现,即药品临床;药物品种多,则是药物研发情况的表现,即临床药品。临床试验直观反映了药品的有效性及安全性,又侧面折射出药物研发的状态与进展。下面本文将对我国药品临床与临床药品(1类新药)做逐一分析:1、我国临床试验(CTR)情况研究-药品临床2013年9月6日,我国国家食品药品监督管理总

中科院报告:中国研究前沿度全球第二,但临床研究仅排13,“高血压强化降压治疗”研究最热

由中国科学院科技战略咨询研究院、中国科学院文献情报中心与科睿唯安联合发布了《2018研究前沿》报告和《2018研究前沿热度指数》报告。

中国率先启动抗呼吸道合胞病毒临床研究

随着冬季寒冷气候的到来,感冒的病人开始逐渐增多,去年流感疫情的影响,让很多老百姓对“感冒”的了解和重视逐渐加强,但需要向大家明确的是,“感冒”并不都是“流感”,呼吸道合胞病毒(RSV)也是主要元凶之一。大部分成人感染这种病毒后,临床症状跟一般的流感导致的上呼吸道感染症状差不多,会出现流鼻涕咳嗽等。